CLAIMS

What is claimed is

1. Use of a HPV vaccine composition in the manufacture of a medicament for treatment of a patient having cancer, wherein the treatment comprises the steps of:

    a) to be administered to a patient 27 years of age or older or a patient previously not immunized with an HPV vaccine, a first dose of an HPV vaccine which is free of host-cell peptide, polypeptide, or protein or a degradant product thereof;

    b) to be administered to the patient a second dose of the HPV vaccine in one month to three months after the first administration; and

    c) to be administered to the patient a third dose of the HPV vaccine in five months to seven months after the first dose.

2. The use according to claim 1 wherein the second dose of HPV vaccine is to be administered in two months after the first dose is to be administered and the third dose of HPV vaccine is to be administered in six months after the first dose is to be administered.

3. The use according to claim 1 wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprising HPV L1 proteins and HPV multivalent (types 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine comprising HPV L1 proteins.

4. The use according to claim 1 wherein the vaccine is substantially free of host-cell early antigen, E6 or E7.

5. The use according to claim 1 wherein the treatment does not comprise or excludes an additional or other immunostimulant or adjuvant to be administered.

6. The use according to claim 1 wherein the size of the cancer is substantially reduced.

7. The use according to claim 1 wherein the cancer is eliminated.

8. The use according to claim 1 whereby the incidence of recurrence of the cancer is reduced.

9. The use according to claim 1 wherein each dose of HPV vaccine is 0.5 ml.

10. The use according to claim 1 wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and melanoma.

11. The use according to claim 1 characterized by establishing a positive diagnosis of cancer prior to the first dose of HPV vaccine is to be administered.

12. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a patient having cancer, said treatment comprising the step of:

    a) to be administered a dose of an HPV vaccine directly to the cancer or an area immediately surrounding the cancer.

13. The use according to claim 12, further comprising the steps of :

b) to be administered a second dose of the HPV vaccine directly to the cancer or an area immediately surrounding the cancer in one month to three months after the first dose is to be administered; and

c) optionally, to be administered a third dose of the HPV vaccine directly to the cancer or an area immediately surrounding the cancer in five months to seven months after the first dose is to be administered.

14. The use according to claim 13 wherein the second dose of HPV vaccine is to be administered in two months after the first dose is to be administered and the third dose of HPV vaccine is to be administered in six months after the first dose is to be administered.

15. The use according to claim 12 wherein the cancer is eliminated or substantially reduced in size.

16. The use according to claim 12 whereby the incidence of recurrence of the cancer is reduced.

17. The use according to claim 12 wherein the dose of HPV vaccine administered is 0.5 ml.

18. The use according to claim 12 wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and melanoma.

19. The use according to claim 12 characterized by establishing a positive diagnosis of cancer prior to the first dose of HPV vaccine is to be administered.

20. The use according to claim 12 wherein the vaccine is to be administered by injection.

21. The use according to claim 12 wherein the treatment does not comprise or excludes an additional or other immunostimulant or adjuvant to be administered.

22. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a patient having a cancerous tumor, wherein the treatment comprises the steps of:

a) to be administered to a patient having a cancerous tumor, and being 27 years of age or older or a patient previously not immunized with an HPV vaccine, a first dose of an HPV vaccine comprising at least one viral L1 protein which is free of non-L1 viral peptide, polypeptide, or protein or a degradant product thereof;

b) to be administered to the patient a second dose of the HPV vaccine in one month to three months after the first administration; and

c) to be administered to the patient a third dose of the HPV vaccine in five months to seven months after the first dose.

23. The use according to claim 22 wherein the second dose of HPV vaccine is to be administered in two months after the first dose is to be administered and the third dose of HPV vaccine is to be administered in six months after the first dose is to be administered.

24. The use according to claim 22 wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprising HPV L1 proteins and HPV multivalent recombinant vaccine comprising HPV L1 proteins of HPV types 16, 18, 31, 33, 45, 52, and 58.

25. The use according to claim 22 wherein the treatment does not comprise or excludes a second composition comprising an immunostimulant or an adjuvant to be administered.

26. The use according to claim 22 wherein the cancerous tumor is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and melanoma.

27. Use of a HPV vaccine composition in the manufacture of a medicament for the treatment of a patient having a cancerous tumor, wherein the treatment comprises the steps of:

a) to be administered a dose of an HPV vaccine to patient with a cancerous tumor, wherein administration is directly into said tumor; and

b) to be administered a second dose of HPV vaccine in two months after the first dose is to be administered and the third dose of HPV vaccine is to be administered in six months after the first dose is to be administered.

28. The use according to claim 27, further comprising the steps of:

c) to be administered a second dose of the HPV vaccine directly to the cancerous tumor, in one month to three months after the first dose is to be administered; and

d) optionally, to be administered a third dose of the HPV vaccine directly to said cancerous tumor in five months to seven months after the first dose is to be administered.

29. The use according to claim 27 wherein the cancerous tumor is eliminated or substantially reduced in size.

30. The use according to claim 27 whereby recurrence of cancer is reduced.

31. The use according to claim 27 wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and melanoma.

32. The use according to claim 27 wherein the vaccine is to be administered by injection.

33. The use according to claim 27 wherein the treatment does not comprise or excludes to be administered a second composition comprising an immunostimulant or adjuvant.